Updated:
Reaction Biology Corp.
Reaction Biology was founded in 2001 in Malvern, Pennsylvania, to offer kinase-based drug discovery services.
Reaction Biology Corp.
Reaction Biology was founded in 2001 in Malvern, Pennsylvania, to offer kinase-based drug discovery services. The company has since expanded to four sites including Hershey, Pennsylvania, and two locations in Germany: Freiburg and Heidelberg. The firm provides preclinical drug discovery from target validation through hit identification and lead optimization. Its services cover kinase screening, biochemical and cellular assays, immuno-oncology, and in vivo efficacy studies across small molecules, antibodies, ADCs, oncolytic viruses, and bacteria-based agents. The company also offers integrated drug discovery programs on a fee-for-service or partnership basis. Reaction Biology operates under an ISO 9001:2015-certified quality system at its European facilities and maintains BSL2-equipped labs for in vivo work. Reaction Biology participates in the Chemical Biology Consortium (CBC) within the NCI Experimental Therapeutics (NExT) Program alongside partners including the University of California, San Francisco, Evotec, Pharmaron, and the Scripps Research Institute. The company reported over 2,000 clients globally as of its website in 2026. No recent operational event was publicly disclosed. Reaction Biology structures itself as a contract research organization serving pharmaceutical, biotech, and academic clients. Its involvement in the NExT program positions it within government-academia-industry collaborations for cancer drug discovery, a differentiator from purely commercial CROs.
General information
Firm type
other
Year founded
2001
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Malvern
Corporate office
Malvern, PA, United States
Additional offices
Hershey, PA, United States · Freiburg, Germany · Heidelberg, Germany
Frequently asked questions
What services does Reaction Biology offer?
Reaction Biology provides preclinical drug discovery services including kinase screening, biochemical and cellular assays, immuno-oncology assays, and in vivo efficacy studies. It also offers integrated drug discovery programs from target validation through lead optimization. The company works across small molecules, antibodies, ADCs, oncolytic viruses, and bacteria-based agents (per the firm, 2026).
Who are Reaction Biology's typical clients?
The firm serves pharmaceutical, biotech, and academic organizations globally. As of its website, it has worked with over 2,000 clients, including institutions such as the University of California, San Francisco, Emory University, Vanderbilt University, and Pharmaron (per the firm, 2026).
Does Reaction Biology operate only in the US?
No. Reaction Biology has research facilities in Malvern and Hershey, Pennsylvania, and two locations in Germany: Freiburg and Heidelberg. Its European operations are ISO 9001:2015-certified (per the firm, 2026).
What is Reaction Biology's involvement with the NExT Program?
Reaction Biology is a Specialized Center in the Chemical Biology Consortium (CBC) of the NCI Experimental Therapeutics (NExT) Program. It provides focused technologies to support discovery projects in epigenetic, kinase, and other cancer areas alongside government and academic partners (per the firm, 2026).
Is Reaction Biology structured as a single family office?
No. Reaction Biology is a contract research organization (CRO), not a family office. It operates as a commercial preclinical drug discovery service provider and has no disclosed ownership structure indicating family-office status.
What quality certifications does Reaction Biology hold?
Reaction Biology Europe operates under an ISO 9001:2015-certified quality management system for its recombinant protein products, assay services, and in vivo testing. The company also has BSL2-equipped labs for in vivo efficacy studies (per the firm, 2026).
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: